Innovating Works

ARTHEX BIOTECH

Activa
fight-dm1: First In class oliGo THerapy for Myotonic Dystrophy type 1 (DM1) ARTHEX BIOTECH tramitó un HORIZON EUROPE: HORIZON-EIC-2022-ACCELERATORCHALLENGES-01 Myotonic dystrophy type 1 (DM1) is a clinically and genetically heterogeneous disorder with more than 1 million diagnosed patients worldwide...
2022-12-21 - 2025-06-30 | Financiado
CONTRA CANCRUM: Clinically Oriented Translational Cancer Multilevel Modelling IDRYMA TECHNOLOGIAS KAI EREVNAS tramitó un FP7: The ContraCancrum i.e. the Clinically Oriented Translational Cancer Multilevel Modelling project aims at developing a composite multilevel p...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.